N
onadherence to maintenance medications in inflammatory bowel diseases (IBDs) is associated with a 5-fold increase in relapse risk. 1 Nonetheless, 40% to 60% of patients continue to be nonadherent 2 due to factors including time constraints, beliefs about treatment efficacy, side effects, and forgetfulness. 3 Although a proportion of patients are adherent for unintentional reasons, such as simply forgetting or running out of medications, intentional nonadherence accounts for up to a third of cases. 2 Young adults (YAs) are at elevated risk of nonadherence due to risk-taking behavior, rejection of authority, cosmetic side effects, and reduced parental involvement. 3 Dramatic declines in medication adherence during the transitional period is well recognized in type 1 diabetes, which results in poorer glycemic control in some studies 4, 5 but not others. [6] [7] [8] After transition of renal transplantation subjects, increased serum creatinine and allograft loss in 8 out of 20 renal transition recipients was reported. 9 Other studies, however, did not identify these negative outcomes. 10, 11 Significant deviations in serum tacrolimus levels in transitional liver transplantation subjects as compared to pediatric and adult control groups has been demonstrated, 12 suggesting nonadherence may influence medication usage during this critical time period.
There are currently no prospective studies on nonadherence in transitional subjects with IBD. The salient symptomology in IBD of diarrhea and abdominal pain might encourage adherence throughout the transitional period, as opposed to asymptomatic diseases such as solid organ transplantation. Therefore, the primary outcome of this study is to prospectively compare medication adherence rates in transitioned (TR) subjects with YAs who were diagnosed in adult services and hence never experienced transition. The primary null hypothesis is that the TR group is noninferior to YAs. Data were also collected from pediatric patients as a pretransition control group. We further aimed to evaluate the effect of the Inflammatory Bowel Diseases Pharmacist Adherence Counselling (IPAC) intervention 13 on nonadhering patients to determine if this intervention may improve adherence to IBD maintenance medications.
MATERIALS AND METHODS

Clinical Setting
Concord General Hospital, Westmead Public Hospital, and Norwest Private Hospital are adult hospitals within the catchment area of The Children's Hospital at Westmead, a tertiary pediatric hospital in Sydney, Australia. All hospitals run regular IBD clinics and participate in transition care of IBD subjects. In Australia, gastroenterologists manage IBD and the transfer age is typically 18 years. Patients are seen in adult clinics henceforth. About 1/3 of patients are more complex with psychological issues or unstable disease, and they are TR by alternating consultations between the pediatric and adult sites before formal transfer.
Subjects
Subjects diagnosed with IBD by usual endoscopic, radiological, and histological criteria were prospectively recruited from 2012 to 2015 during IBD clinic visits. Patients recruited were aged 12 to 18 years old from the children's hospital ("pediatric subjects," PED), and under 25 year olds from the adult hospitals. These subjects were further stratified into "Transitioned" if they were initially managed by pediatric gastroenterologists, and "Young adult" if they were always managed by adult gastroenterologists. Patients without a definite diagnosis of IBD and those not prescribed IBD medications (e. g., after resectional surgery) were excluded. Patients taking exclusive enteral nutrition were also excluded.
Data Collection
Adherence to medications was assessed with the 4-item Medication Adherence Reporting Scale (MARS). 14 The MARS has been validated in a range of patient populations including IBD. 15, 16 Items are scored on a 5-point Likert scale and summed to yield a total score between 4 and 20 ( Table 1) . Participants scoring #16 were classified as nonadherers, and $17 were classified as adherers. 14 Beliefs about prescription medications were assessed with the validated Beliefs about Medicines Questionnaire (BMQSpecific). 17 This questionnaire has two 5-item subscales which assess, respectively, the patient's beliefs about the necessity of medications in managing illness, and concerns relating to side effects of the medication. An example of a necessity question is "My health in the future will depend on these medicines." An example of a concerns question is "Having to take these medicines worries me." Each question is scored on a 5-point Likert scale: Totally agree (5), Agree somewhat (4), Neither agree nor disagree (3), Disagree somewhat (2), and Disagree totally (1). The 5 questions from each subscale are summated, yielding a total score from 5 to 25. A score of 15 to 25 is defined as high necessity or concern. Medication "acceptance," defined as having high necessity and low concern scores, demonstrably correlates with improved adherence. 14 The MARS and BMQ questionnaires had a Flesch--Kincaid Readability Grade Level of 6.0 and would be appropriate for subjects age 12 and older. 14 The BMQ questionnaire has been validated in children as young as 7 years of age. 18, 19 Pediatric patients completed the questionnaires separately from their parents to minimize parental influence, and parents were blinded to the results. Age, sex, disease phenotype, disease duration, months since transfer, and current medication data were collected.
Inflammatory Bowel Diseases Pharmacist Adherence Counselling (IPAC)
Medication nonadherers (MARS #16) were invited for a structured personalized counselling session performed by a trained IBD pharmacist. Being a third-party independent to the primary prescriber, the IBD pharmacist may also provide a consensus viewpoint on the appropriateness of the medication selected and act as a voice of encouragement for medication adherence. Table 2 summarizes the topics covered during the consultation with the IBD pharmacist. Follow-up MARS and BMQ questionnaires were administered to all subjects 6 months after baseline by telephone contact with the patient independent to their parents. As there were no significant predictors of loss to follow-up, pair-wise deletion of missing follow-up cases was used when comparing follow-up to baseline values.
TABLE 1. Medication Adherence Rating Scale (MARS)
I forget to take these IBD medicines I alter the dose of these IBD medicines I stop taking these IBD medicines for a while I decide to miss out on a dose Each item is scored: Always (5), Often (4), Sometimes (3), Rarely (2), and Never (1). 
Statistical Analysis
Based on the sample sizes of 14 and 20 used by Annunziato et al 12 and Watson 9 to demonstrate inferiority of adherence posttransition, and the large effect size seen in these studies, it was postulated that 30 patients in each group would provide sufficient power to find clinically significant adherence differences between the TR and YA groups. A formal statistical power analysis could not be conducted as the effect size was unknown for our adherence measure. Dependent variables were assessed for normality by visual inspection of the histogram and using quantile-quantile plots. Comparisons across 3 groups were conducted using Kruskal-Wallis and chi-squared tests on continuous and categorical variables, respectively. The Mann--Whitney U test was used for comparisons of nonparametric continuous variables. Descriptive statistics were performed using mean and SD or median and interquartile ranges. Spearman correlation was used to compare 2 nonparametrically distributed continuous variables. Multivariate binary logistic regression (backward LR) was used to evaluate predictors of nonadherence. Variables were screened for association with nonadherence using a cut-off of P , 0.1. The impact of counselling on MARS-rated nonadherence was evaluated for paired data using the McNemar's test on an intention-to-treat basis. A P value of 0.05 (2-sided) was defined as statistical significance. Statistical analysis was completed using SPSS (version 21.0; IBM SPSS Statistics, Armonk, NY). 
ETHICAL CONSIDERATIONS
RESULTS
Demographic and Clinical Characteristics
129 subjects were prospectively recruited comprising 50 PED (mean age 14.7 yrs, 58% male), 38 TR (mean age 20.4, 53% men) and 41 YA (mean age 21.2, 63% men). Seventy-four percentage of subjects had Crohn's disease and 21% had ulcerative colitis (Table 3) . There was no difference in the mean age of diagnosis between the TR (11.1 yrs) and PED (12.2 yrs, P . 0.99) groups but both were significantly younger than YA (18.3 yrs, both P , 0.001). As expected, TR subjects had significantly longer disease duration (mean 9.4 yrs) than YA (3.2 yrs) and PED (2.6 yrs) (both P , 0.001). No significant differences were seen according to sex, number of IBD medicines, or use of specific drug classes. For the TR cohort, mean age at transition was 17.7 years (SD 0.94) and mean time since transition was 30.9 (SD 28.9) months. There was no missing data for any variable of interest at baseline but 12.7% of subjects did not complete follow-up questionnaires because of inability to contact the patient (8.1%), follow-up refusal (1.6%), or stopping IBD medications in agreement with the treating doctor (2.4%).
Primary Outcome
The TR cohort did not have lower adherence compared with the YA group. Nonadherence rates were numerically greater for YA (24.4%) compared with TR (13.2%), but this did not reach significance (P ¼ 0.203, Fig. 1 ). Eight percentage of the PED control group were nonadherent, significantly less than YA (P ¼ 0.03) but not TR (P ¼ 0.43).
Secondary Outcomes
Ninety-eight percentage of the study population had high belief in medication Necessity with no significant intergroup differences (Fig. 2) . Fifty-six percentage had high medicationrelated concerns, with the YA cohort having significantly greater concerns than the PED group (P ¼ 0.02). There were no significant associations between MARS, necessity and concerns scores. Duration since transfer and age at transfer were not predictive of MARS-rated adherence in the TR group.
Predictors of Nonadherence
Protective factors (OR 95% confidence interval) were PED group membership (0.05-0.85) and corticosteroid use (0.01-0.84), while aminosalicylate use was a risk factor (2.19-28.8) . Older age, disease duration, age at diagnosis, disease phenotype, number of medications, anti-TNF use, immunomodulatory use, and hospital of origin were not included in the final regression equation.
Adherence Counselling and Follow-up
Of the 17 baseline nonadherers, 13 received the IPAC intervention. At a mean follow-up of 240 days (SD 85), counselling significantly decreased nonadherence rates by 60% (P ¼ 0.004). Sensitivity to uncontactable subjects was tested by conservatively assuming that their MARS score dropped by 1 at follow-up; the effect of IPAC remained statistically significant (P ¼ 0.019).
Numerical improvement in MARS occurred in all 3 groups of nonadherers but was statistically significant only in the never-TR group (P ¼ 0.011). Mean necessity belief score reduced from 19.8 to 19.1 (P ¼ 0.151) and concerns score increased from 12.2 to 12.9 (P ¼ 0.573) but were not statistically significant.
DISCUSSION
Evidence from type 1 diabetes mellitus and solid organ transplantation 4, 9, 12, 20 indicates that transition is a high-risk time period for medication nonadherence. However, the validity of extending this conclusion to a disease of salient symptomatology such as IBD is dubious. This is the first study to deliver crosssectional prospective adherence data relating to IBD medications around the time of transition. The result demonstrates clear noninferiority of TR patients (13.2% nonadherent) with the YA group having numerically worse adherence (24.4%). Salient IBD symptoms of diarrhea and abdominal pain provide negative reinforcement in the social context of transition-aged patients, encouraging adherence through teenage years. Reflecting this, 98% of subjects had high necessity scores. Corticosteroids, usually used for remission induction, were protective against nonadherence, whereas aminosalicylates, relatively low-efficacy agents, predicted poor adherence.
Nonadherence rates were very low (8.0%) in the PED control group. This may be because of parental oversight and the pediatric service providing multidisciplinary supportive care, longer clinic appointments, education, and close personal monitoring by the consultant gastroenterologist. IBD nurses and pharmacists may address any concerns about medications, and therapeutic drug monitoring ensures safety during follow-up. In our study, adherence differences between the PED and TR groups and TR and YA groups were nonsignificant. These may be true negatives, or because of inadequate sample size for small effect sizes. Key influences include the benefit of management in a pediatric hospital continuing into young adulthood for the TR group and high medication-related concerns in YAs causing poor adherence.
This study also demonstrated that a counselling intervention by an IBD pharmacist can improve adherence on longitudinal follow-up. Use of the Health Beliefs model assisted the counselling process in targeting medication Necessity beliefs and/or medication concerns. Previous interventional studies using reminder strategies were unable to demonstrate improvement to adherence, probably because they did not address intentional nonadherence. As this study was not powered to recapitulate previously found associations between adherence and beliefs about medicines, 13 it cannot be discounted that the intervention worked as a reminder, improving adherence without changing underlying beliefs. Moreover, the costeffectiveness of pharmacist counselling bears mention and needs further inquiry.
Some limitations of this study must be acknowledged. Even though the MARS questionnaire has been tested in IBD and other chronic illnesses, 14, 15, 21 it is nevertheless a subjective measure in contrast to objective drug levels. However, the questionnaires were administered independent to the consultation process by a researcher not involved in the patient's care, reducing embarrassment by the study subject during consultation.
It is possible that PED patients underreported nonadherence despite our efforts to separate them from their parents during the questionnaire. This would not explain why only 13.2% of the TR cohort reported low adherence, as their parents were absent in most cases. Generalizability may be limited by our region-specific transition scheme, but data across the 3 adult catchment hospitals were similar indicating consistency of results. Although loss to follow-up was low (12.7%), selective loss of nonadherent patients may have inflated follow-up adherence scores. Our sensitivity analysis indicated that the effect of counselling was robust against loss to follow-up. An alternate study design of a longitudinal pediatric cohort study might be preferable over our cross-sectional cohort design. However, it would take years to complete the study following pediatric subjects until they have transitioned to adult care. Loss to follow-up might be significant using this strategy. Our study included longitudinal follow-up of a nonadherer cohort that demonstrated significantly improved adherence rates on paired analyses.
There may be alternate reasons why the YA group had a higher nonadherence rate of 24.4%, such as age at diagnosis, short disease duration, and current age, but none of these variables were predictive of nonadherence. Adherence might be worse with short disease duration (shortest in the YA group). However, data from another study found 23.5% nonadherence in an IBD cohort with a median age of 37 years, suggesting that the nonadherence rate of the YA cohort may be one that reflects adult IBD patients as a whole. 13 The YA group had a low rate of ulcerative colitis (39%) and aminosalicylate use rate (22%). Older cohorts with higher ulcerative colitis and aminosalicylate use rates 22 may have even worse adherence. More generally, longer follow-up may reveal other differences between TR and YA groups, such as hospital admissions, surgery rates, and clinical remission rates. 23 In conclusion, TR patients did not have worse adherence than YAs diagnosed in adulthood, contrary to literature on type 1 diabetes mellitus and organ transplantation. The motivational influence of IBD symptoms and beneficial effects of previous treatment in pediatric care may be protective in these patients, whereas YAs have greater concerns over medications. We demonstrated the efficacy of Inflammatory Bowel Diseases Pharmacist Adherence Counselling and recommend this role in the multidisciplinary management of IBD.
